Kovitz Investment Group Partners LLC Boosts Holdings in Bristol Myers Squibb Company $BMY

Kovitz Investment Group Partners LLC increased its stake in shares of Bristol Myers Squibb Company (NYSE:BMY) by 2.3% during the 3rd quarter, Holdings Channel reports. The fund owned 795,782 shares of the biopharmaceutical company’s stock after purchasing an additional 18,128 shares during the quarter. Kovitz Investment Group Partners LLC’s holdings in Bristol Myers Squibb were worth $35,890,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in BMY. Gateway Investment Advisers LLC raised its position in Bristol Myers Squibb by 10.0% during the third quarter. Gateway Investment Advisers LLC now owns 113,457 shares of the biopharmaceutical company’s stock worth $5,117,000 after acquiring an additional 10,284 shares during the period. CWA Asset Management Group LLC grew its holdings in shares of Bristol Myers Squibb by 25.9% during the third quarter. CWA Asset Management Group LLC now owns 150,359 shares of the biopharmaceutical company’s stock worth $6,781,000 after buying an additional 30,909 shares in the last quarter. Commonwealth Retirement Investments LLC grew its stake in Bristol Myers Squibb by 24.6% during the 2nd quarter. Commonwealth Retirement Investments LLC now owns 59,183 shares of the biopharmaceutical company’s stock valued at $2,740,000 after acquiring an additional 11,690 shares in the last quarter. Stephens Inc. AR raised its holdings in Bristol Myers Squibb by 13.5% in the 3rd quarter. Stephens Inc. AR now owns 273,343 shares of the biopharmaceutical company’s stock valued at $12,328,000 after acquiring an additional 32,476 shares during the last quarter. Finally, Railway Pension Investments Ltd lifted its stake in Bristol Myers Squibb by 3.7% in the 3rd quarter. Railway Pension Investments Ltd now owns 1,139,600 shares of the biopharmaceutical company’s stock worth $51,396,000 after purchasing an additional 40,300 shares in the last quarter. Hedge funds and other institutional investors own 76.41% of the company’s stock.

Key Headlines Impacting Bristol Myers Squibb

Here are the key news stories impacting Bristol Myers Squibb this week:

• Positive Sentiment: Barclays initiated U.S. large‑cap biopharma coverage and included Bristol‑Myers Squibb among four preferred picks, arguing the sector could regain investor attention and highlighting BMY as a top choice. This institutional endorsement likely helped buying interest. Barclays launches U.S. biopharma coverage with four preferred picks
• Positive Sentiment: BMY reported completion of a mavacamten safety‑extension study update, which clarifies the long‑term safety profile for its hypertrophic cardiomyopathy program — a de‑risking event for a later‑stage asset and a potential long‑term revenue driver. BMY’s Mavacamten Safety Extension Wraps Up
• Positive Sentiment: Analyst/commentary pieces highlight BMY’s oncology franchise and new drug launches, noting cost cuts and a stronger 2026 outlook versus peers — reinforcing confidence in revenue stability and medium‑term growth. Bristol‑Myers Squibb: Oncology Franchise Remains A Core Strength
• Neutral Sentiment: Comparative analyst coverage (Zacks/Money pieces) argues BMY edges Merck in the 2026 setup due to product launches and cost actions — a relative positive versus peers but not new company‑specific catalysts. Merck vs. Bristol Myers: Which Pharma Stock Is a Better Pick in 2026?
• Neutral Sentiment: Coverage discussing an Iberdomide regulatory review and an AI partnership adds new angles to BMY’s mid‑cycle outlook; informative for pipeline expectations but not an immediate earnings swing. Iberdomide Review And AI Alliance Add New Angles To BMY Outlook
• Negative Sentiment: Zacks Research issued a series of downward revisions to several near‑term EPS estimates (notably Q1/Q2 2026 and FY2027 trims), which introduces caution around short‑term earnings momentum and could cap upside until upcoming results confirm guidance.

Bristol Myers Squibb Trading Up 0.6%

Shares of BMY stock opened at $60.66 on Monday. Bristol Myers Squibb Company has a 1-year low of $42.52 and a 1-year high of $63.33. The firm has a market cap of $123.53 billion, a PE ratio of 17.58, a price-to-earnings-growth ratio of 0.17 and a beta of 0.29. The company has a 50-day moving average of $56.22 and a two-hundred day moving average of $50.03. The company has a debt-to-equity ratio of 2.32, a current ratio of 1.26 and a quick ratio of 1.14.

Bristol Myers Squibb (NYSE:BMY) last released its quarterly earnings results on Thursday, February 5th. The biopharmaceutical company reported $1.26 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $1.65 by ($0.39). The company had revenue of $12.50 billion during the quarter, compared to analysts’ expectations of $12.24 billion. Bristol Myers Squibb had a net margin of 14.64% and a return on equity of 69.65%. Bristol Myers Squibb’s revenue was up 1.3% on a year-over-year basis. During the same period last year, the firm posted $1.67 earnings per share. Bristol Myers Squibb has set its FY 2026 guidance at 6.050-6.350 EPS. On average, analysts predict that Bristol Myers Squibb Company will post 6.74 EPS for the current year.

Bristol Myers Squibb Increases Dividend

The company also recently declared a quarterly dividend, which was paid on Monday, February 2nd. Stockholders of record on Friday, January 2nd were given a dividend of $0.63 per share. This is an increase from Bristol Myers Squibb’s previous quarterly dividend of $0.62. This represents a $2.52 annualized dividend and a dividend yield of 4.2%. The ex-dividend date was Friday, January 2nd. Bristol Myers Squibb’s dividend payout ratio (DPR) is 73.04%.

Analyst Upgrades and Downgrades

Several equities research analysts recently commented on BMY shares. Cantor Fitzgerald reaffirmed a “neutral” rating on shares of Bristol Myers Squibb in a report on Monday, November 24th. Scotiabank restated a “sector perform” rating and issued a $60.00 target price (up from $53.00) on shares of Bristol Myers Squibb in a report on Friday, January 9th. HSBC reaffirmed a “hold” rating and issued a $53.00 target price on shares of Bristol Myers Squibb in a research note on Wednesday, December 10th. Citigroup boosted their price target on shares of Bristol Myers Squibb from $60.00 to $64.00 and gave the company a “neutral” rating in a research report on Friday, February 6th. Finally, Sanford C. Bernstein reissued a “market perform” rating on shares of Bristol Myers Squibb in a report on Monday, November 3rd. Nine research analysts have rated the stock with a Buy rating, eleven have given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus price target of $60.19.

About Bristol Myers Squibb

Bristol Myers Squibb is a global biopharmaceutical company headquartered in Princeton, New Jersey, focused on discovering, developing and delivering medicines for serious diseases. The company’s core activities include research and development, clinical development, manufacturing and commercialization of prescription pharmaceuticals across multiple therapeutic areas. BMS concentrates on advancing therapies in oncology, hematology, immunology, cardiovascular disease and specialty areas through both small molecules and biologics.

BMS’s marketed portfolio and late‑stage pipeline reflect a strong emphasis on cancer and immune‑mediated conditions.